Shares of the IBD 50's GeneDx surged Monday after the Food and Drug Administration issued guidance about using AI to develop ...
TD Cowen raised the firm’s price target on GeneDx (WGS) to $118 from $75 and keeps a Buy rating on the shares. The firm reviewed its financial ...
GeneDx Holdings Corp. WGS shares soared 13.2% in the last trading session to close at $89.61. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...
TD Cowen analyst Daniel Brennan maintained a Buy rating on GeneDx Holdings (WGS – Research Report) today and set a price target of $118.00. The ...
Shares of IBD 50's GeneDx surged Monday after the Food and Drug Administration issued guidance about using AI to develop medical devices.
STAMFORD, Conn., January 02, 2025--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Bryan Dechairo as Chief ...
GeneDx Holdings Corp. (NASDAQ:WGS – Get Free Report) has been given an average rating of “Moderate Buy” by the six brokerages ...
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the ...
GeneDx (WGS) is among the best performing small cap stocks for 2024, posting over 2600% gain. The company analyzes the complete DNA of a person, also known as the genome, composed of approximately ...
NEW YORK – After two years of decline in 2022 and 2023, the 360Dx Top 30 rebounded in 2024, rising 4 percent year over year.
GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and ...
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Bryan Dechairo as Chief ...